Extended Data Fig. 4: Effect of TET2 editing on CAR T cell accumulation in a prostate cancer model.
From: TET2 guards against unchecked BATF3-induced CAR T cell expansion
a, Schematics of the prostate cancer experimental design. TET2 was edited with the previously discussed gRNA (g1) and an alternative gRNA (g2). PSMA28z+41BBL (PSMA targeted, CD28 costimulated CAR that expresses 41BBL ligand) was used in this study (Dose: 2e5). b, CAR T cell counts in the peripheral blood 30 days post infusion of T cells. Bars show median values. c, Mice with the top 4 CAR T cell peripheral counts at day 30 across both TET2 targeting gRNA (g1, n = 2. g2, n = 2) were euthanized at day 45 along with 5 scrambled gRNA treated PSMA28z+41BBL mice and their splenic CAR T cell numbers were quantified. p values were determined by two-sided Mann-Whitney (b, c) [n = 5 (WT PSMA28z+41BBL), n = 8 (TET2etdg1 PSMA29z+41BBL), n = 11 (TET2etdg2 PSMA29z+41BBL)]. p < 0.05 was considered statistically significant. p values are denoted: *, p < 0.05; **, p < 0.01. Exact p values are available in Supplementary Table 4. The mouse illustration in part a was generated using Servier Medical Art, CC BY 3.0.
